Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Binding of F9170 to HIV-1 gp120 and gp140.
  • Fig. S2. Percent change of in IC50 of F9170 mutant peptides for inhibiting HIV-1 BaL infection, compared with that of F9170 peptide.
  • Fig. S3. Infectivity of mutated and wild-type pseudo-virus to TZM-bl target cells.
  • Fig. S4. Cytotoxicity of F9170 to reactivated latently infected cells.
  • Fig. S5. Safety of F9170 in mice.
  • Fig. S6. Inhibitory activity of F9170 against HIV-1 IIIB infection in MT-2 cells.
  • Fig. S7. Distribution of F9170 in mice.
  • Fig. S8. Safety of F9170 in the CNS of mice.
  • Fig. S9. F9170 serum concentration in F9170-treated mice at different time point after intravenous injection.
  • Fig. S10. Safety of F9170 in the CNS of SHIV-infected rhesus macaques.
  • Table S1. Inhibitory activity of F9170 against HIV-1 laboratory-adapted strains, primary isolates, and T20-resistant strains.
  • Table S2. Inactivation of cell-free HIV-1 R5 and X4 strains by F9170.
  • Table S3. Clinical information of 10 patients with HIV whose blood were tested for preexisting antibodies to F9170.
  • References (7178)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: